Organotin complexes with Schiff’s base ligands: insights into their cytotoxic effects on lung cancer cells

Organotin(IV) complexes can be used in chemotherapy due to its lipophilicity which can be affected by the availability of Sn coordination bond and bond stabilization between ligand and Sn(IV). In this study, three types of tri-organotin(IV) complexes which are, Ph 3 SnL, Me 3 SnL, and Bu 3 SnL deriv...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Umm Al-Qura University for Applied Sciences 2024-06
Hauptverfasser: Ibadi, Falih, Yousif, Emad, Al-Ani, Ahmed, Al-Mashhadani, Mohammed, Al-Saffar, Ali Z., Basem, Ali, Bufaroosha, Muna, Hashim, Hassan, Husain, Amani, Jawad, Ali H., Hairunisa, Nany
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Organotin(IV) complexes can be used in chemotherapy due to its lipophilicity which can be affected by the availability of Sn coordination bond and bond stabilization between ligand and Sn(IV). In this study, three types of tri-organotin(IV) complexes which are, Ph 3 SnL, Me 3 SnL, and Bu 3 SnL derived from Schiff base ligand were synthesized by the reaction of methyl dopa with p-dimethyaminobenzaldehyde. All prepared complexes were charechterised using nuclear magnetic resonance ( 1 H NMR, 13 C NMR, and 119 Sn NMR. The 1 H NMR). The results confirm the coordination of the organotin(IV) moieties to the ligand. The cytotoxicity of tri-organotin(IV) complexes was evaluated against the A549 human lung cancer cell using MTT assay. Ph 3 SnL showed a high cytotoxic effect among othger complexes, Bu 3 SnL also showed a significant cytotoxic effect, while Me 3 SnL demonstrated a relatively lower effects. These findings highlight the potential of the tri-organotin(IV) complexes, particularly Ph 3 SnL and Bu 3 SnL, as promising candidates for further modification as anticancer agents. The results obtained from this study can be used to understand the structure–activity of organotin(IV) complexes and their applications as anti-cancer activity.
ISSN:2731-6734
1658-8185
DOI:10.1007/s43994-024-00170-w